<DOC>
	<DOCNO>NCT00325286</DOCNO>
	<brief_summary>This open label design use Lithium plus extended release carbamazepine ( Equetro ) combination 6 month . Rapid cycle bipolar disorder frequently treatment refractory associate repeated hospitalization complication . The result study offer promise approach treat complex disorder . The primary efficacy measure time relapse . Relapse determine investigator base following : Need additional pharmacotherapy mood-related symptom , hospitalization mood episode , increase 50 % HAM-D YMRS score baseline visit .</brief_summary>
	<brief_title>Open Label Study Lithium Plus Extended-Release Carbamazepine ( ERC-CBZ ) Rapid Cycling Bipolar Disorder</brief_title>
	<detailed_description>Open label Design Lithium plus Extended release carbamazepine combination 6 month . Extended release carbamazepine dose 1600 mg/day utilize . Lithium dosage adjust maintain therapeutic blood level . Patient Population : N = 20 . Primary Secondary Efficacy Endpoints : The primary efficacy measure time relapse . Relapse determine investigator base follow - Need additional pharmacotherapy affective symptom - Hospitalization affective episode - Increase 50 % HAM-D YMRS score baseline The difference frequency affective episode 6-month prior treatment ERC-CBZ 6 month treatment initiation also measure . Secondary efficacy measure include ; change 17- Item Hamilton Depression Scale ( HAM-D ) , Young Mania Rating Scale ( YMRS ) , Clinical Global Severity Scale ( CGI -S ) , Clinical Global Improvement Scale ( CGI-I ) score baseline score treatment ERC-CBZ . Inclusion Criteria : 1 . Subjects , 19 year old DSM-IV define Bipolar Disorder history rapid cycling within past 12 month . 2 . Subjects may either manic , mixed depressive phase time study entry . 3 . Subjects must lithium therapy 6 month longer . Stable lithium therapy define : No change lithium dosage least 2 week prior study entry therapeutic lithium level ( 0.6 1.2 mEq ) prior study entry . Exclusion Criteria : 1 . Subjects lifetime history Schizophrenia Schizoaffective Disorder 2 . If patient thyroid replacement therapy stable dos past 3 month study enrollment . 3 . Presence active suicide ideation score &gt; 3 suicide subscale 17 - item HAM-D. 4 . Current substance dependence ( exclude nicotine ) define dependence criterion 30 day prior study enrollment 5 . Subjects history non-response carbamazepine lithium 6 . Subjects pregnant plan become pregnant 7 . Subjects history allergic/idiosyncratic reaction intolerability carbamazepine lithium . Study Procedures : Preliminary Phase : The Structured Clinical Interview Diagnostic Schedule ( SCID ) , medical &amp; psychiatric history baseline laboratory testing , EKG ; pregnancy test obtain ensure study eligibility . Eligible subject receive ERC-CBZ start dos range 100 200 mg b.i.d . depend clinical presentation titration maximum dose 1600 mg/day do discretion investigator . This titration phase extend beyond 2 week change concomitant medication allow . Next , psychotropics exclude lithium , ERC-CBZ benzodiazepine taper 2-week period . During preliminary phase subject see weekly assessment make use HAM-D , YMRS , CGI -S , CGI-I , AE , Concomitant medication Open Label Phase : Subjects lithium ERC-CBZ therapy enter phase 6 month . Changes lithium ERC-CBZ permit phase serum level guide titration . Use lorazepam , rescue medication permit . Study visit every biweekly 6 month . The HAM-D , YMRS CGI-S , CGI-I , AE , concomitant medication assess visit . Compliance assess pill count study visit .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Lithium Carbonate</mesh_term>
	<mesh_term>Carbamazepine</mesh_term>
	<criteria>1 . Subjects , 19 year old DSMIV define Bipolar Disorder history rapid cycling within past 12 month . 2 . Subjects may either manic , mixed depressive phase time study entry . 3 . Subjects must lithium therapy 6 month longer . Stable lithium therapy define : No change lithium dosage least 2 week prior study entry therapeutic lithium level ( 0.6 1.2 mEq ) prior study entry . 1 . Subjects lifetime history Schizophrenia Schizoaffective Disorder 2 . If patient thyroid replacement therapy stable dos past 3 month study enrollment . 3 . Presence active suicide ideation score &gt; 3 suicide subscale 17 item HAMD . 4 . Current substance dependence ( exclude nicotine ) define dependence criterion 30 day prior study enrollment 5 . Subjects history nonresponse carbamazepine lithium 6 . Subjects pregnant plan become pregnant 7 . Subjects history allergic/idiosyncratic reaction intolerability carbamazepine lithium .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>